72760-87-3

Usage

Uses

Used in Pharmaceutical Synthesis:
5-amino-3-methoxy-1H-pyrazole-4-carbonitrile is used as an intermediate in the synthesis of pharmaceuticals for its unique structure and reactivity. The presence of the amino, methoxy, and carbonitrile groups in its structure allows for a diverse range of chemical reactions, making it a valuable building block for the preparation of various bioactive compounds.
Used in Agrochemical Synthesis:
In the agrochemical industry, 5-amino-3-methoxy-1H-pyrazole-4-carbonitrile is used as an intermediate for the synthesis of agrochemicals. Its unique structure and reactivity contribute to the development of effective and targeted agrochemical products.

Upstream product

• 64672-72-6 2-(dimethoxymethylidene)propanedinitrile 
• 3889-56-3 3-chloro-5-methoxyisothiazole-4-carbonitrile 

Downstream Products

• 111375-42-9 3-methoxy-4,6-bis(methylthio)-pyrazolo<3,4-d>pyrimidine 
• 1607023-97-1 5-(4-chlorophenyl)-2-methoxy-3-(3-methyl-1,2,4-oxadiazol-5-yl)-4H,7H-pyrazolo[1,5-a]pyrimidin-7-one 
• 1607023-96-0 5-(4-chlorophenyl)-N-[(1E)-1-(dimethylamino)ethylidene]-2-methoxy-7-oxo-4H,7H-pyrazolo[1,5-a]pyrimidine-3-carboxamide 
• 1607023-95-9 5-(4-chlorophenyl)-2-methoxy-7-oxo-4H,7H-pyrazolo[1,5-a]pyrimidine-3-carboxamide 
• 111375-30-5 3-Methoxy-1-(2,3,5-tri-O-benzoyl-β-D-ribofuranosyl)pyrazolo<3,4-d>pyrimidin-4(5H)-one 
• 111375-28-1 3-methoxy-1H-pyrazolo<3,4-d>pyrimidin-4(5H)-one 

Relevant academic research and scientific papers

HETEROCYCLIC COMPOUNDS FOR THE INHIBITION OF PASK

Disclosed herein are new heterocyclic compounds and compositions and their application as pharmaceuticals for the treatment of disease. Methods of inhibiting PAS Kinase (PASK) activity in a human or animal subject are also provided for the treatment of diseases such as diabetes mellitus.

Potent and selective aminopyrimidine-based B-Raf inhibitors with favorable physicochemical and pharmacokinetic properties

Recent clinical data provided proof-of-concept for selective B-Raf inhibitors in treatment of B-RafV600E mutant melanoma. Pyrazolopyridine-type B-Raf inhibitors previously described by the authors are potent and selective but exhibit low solubility requiring the use of amorphous dispersion-based formulation for achieving efficacious drug exposures. Through structure-based design, we discovered a new class of highly potent aminopyrimidine-based B-Raf inhibitors with improved solubility and pharmacokinetic profiles. The hinge binding moiety possesses a basic center imparting high solubility at gastric pH, addressing the dissolution limitation observed with our previous series. In our search for an optimal linker-hinge binding moiety system, amide-linked thieno[3,2-d]pyrimidine analogues 32 and 35 (G945), molecules with desirable physicochemical properties, emerged as lead compounds with strong efficacy in a B-RafV600E mutant mouse xenograft model. Synthesis, SAR, lead selection, and evaluation of key compounds in animal studies will be described.

RAF INHIBITOR COMPOUNDS AND METHODS OF USE THEREOF

Compounds of Formula II are useful for inhibition of Raf kinases. Methods of using compounds of Formula II and stereoisomers, tautomers, prodrugs and pharmaceutically acceptable salts thereof, for in vitro, in situ, and in vivo diagnosis, prevention or tr

The conversion of isothiazoles into pyrazoles using hydrazine

The conversion of isothiazoles into pyrazoles on treatment with hydrazine is investigated. The influence of various C-3, C-4 and C-5 isothiazole substituents and some limitations of this ring transformation are examined. When the isothiazole C-3 substituent is a good nucleofuge, 3-aminopyrazoles are obtained. However, when the 3-substituent is not a leaving group it is retained in the pyrazole product. Treatment of 4-bromo-3-chloro-5-phenylisothiazole 56 or 3-chloro-4,5-diphenylisothiazole 57 with anhydrous hydrazine at ca. 200 °C for a few minutes gives the corresponding 3-hydrazinoisothiazoles 61 and 64 respectively in high yields; the stability of these new hydrazines is investigated. 5,5′-Diphenyl-3,3′-biisothiazole-4,4′-dicarbonitrile 78 reacts with hydrazine to give 5,5′-diphenyl-3,3′-bi(1H-pyrazole)-4,4′-dicarbonitrile 79. Methylhydrazine reacts with 3-chloro-5-phenylisothiazole-4-carbonitrile 1 to give 3-(1-methylhydrazino)-5-phenylisothiazole-4-carbonitrile 83 and 3-amino-1-methyl-5-phenylpyrazole-4-carbonitrile 84. All products are fully characterised and rational mechanisms for the isothiazole into pyrazole transformation are proposed.